Literature DB >> 11093789

Glycosylation of the gastrin-releasing peptide receptor and its effect on expression, G protein coupling, and receptor modulatory processes.

R V Benya1, T Kusui, T Katsuno, T Tsuda, S A Mantey, J F Battey, R T Jensen.   

Abstract

Many gastrointestinal G protein-coupled receptors are glycosylated; however, which potential glycosylation sites are actually glycosylated and their role in receptor transduction or receptor modulation (internalization, down-regulation, desensitization) is largely unknown. We used site-directed mutagenesis to address these issues with the gastrin-releasing peptide receptor (GRP-R). Each of the four potential glycosylation sites was mutated by converting the Asn (N) to Gln (Q). Transient expression in CHOP cells demonstrated that changing Asn(24) or Asn(191) inhibited GRP-R cell surface expression, whereas elimination of Asn(5) and Asn(20) had no effect. Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191). Removal of three glycosylation sites (N5,20,24,Q mutant) did not alter receptor affinity or G protein coupling; therefore, it could be speculated that deglycosylation at Asn(191) might be responsible for the altered G protein coupling seen with complete enzymatic deglycosylation of the native receptor previously reported. Removal of any single glycosylation site did not interfere with GRP-R induced chronic desensitization or down-regulation. However, elimination of all three NH(2)-terminal sites (N5,20,24) markedly attenuated both processes, with no effect on acute homologous desensitization and with only a minimal alteration of GRP-R internalization, supporting the findings of other studies that suggest that chronic desensitization and down-regulation are functionally coupled, distinct from acute desensitization and distinct from internalization. These data show that separate and specific glycosylation sites are important for GRP-R trafficking to the cell surface, ligand binding, G protein coupling, chronic desensitization, and down-regulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11093789     DOI: 10.1124/mol.58.6.1490

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  The role of N53Q mutation on the rat mu-opioid receptor function.

Authors:  A Rostami; M Rabbani; M Mir-Mohammad-Sadeghi
Journal:  J Biomol Tech       Date:  2010-07

Review 2.  G Protein-Coupled Receptors in the Sweet Spot: Glycosylation and other Post-translational Modifications.

Authors:  Christoffer K Goth; Ulla E Petäjä-Repo; Mette M Rosenkilde
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-17

3.  Expression of gastrin-releasing peptide is increased by prolonged stretch of human myometrium, and antagonists of its receptor inhibit contractility.

Authors:  Mark Tattersall; Yolande Cordeaux; D Stephen Charnock-Jones; Gordon C S Smith
Journal:  J Physiol       Date:  2012-03-12       Impact factor: 5.182

4.  Localization of beta1-adrenergic receptors in the cochlea and the vestibular labyrinth.

Authors:  C Fauser; S Schimanski; P Wangemann
Journal:  J Membr Biol       Date:  2004-09-01       Impact factor: 1.843

Review 5.  The functional significance of genetic variation within the beta-adrenoceptor.

Authors:  A J Sandilands; K M O'Shaughnessy
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

6.  N-glycan-mediated quality control in the endoplasmic reticulum is required for the expression of correctly folded delta-opioid receptors at the cell surface.

Authors:  Piia M H Markkanen; Ulla E Petäjä-Repo
Journal:  J Biol Chem       Date:  2008-08-14       Impact factor: 5.157

7.  Gastrin-Releasing Peptide Receptor in Low Grade Prostate Cancer: Can It Be a Better Predictor Than Prostate-Specific Membrane Antigen?

Authors:  Pinuccia Faviana; Laura Boldrini; Paola Anna Erba; Iosè Di Stefano; Francesca Manassero; Riccardo Bartoletti; Luca Galli; Carlo Gentile; Massimo Bardi
Journal:  Front Oncol       Date:  2021-03-29       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.